Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Share-based Compensation: 2021-2023

Historic Share-based Compensation for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to $7.5 million.

  • Cullinan Therapeutics' Share-based Compensation rose 0.08% to $7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $30.4 million, marking a year-over-year increase of 8.87%. This contributed to the annual value of $37.8 million for FY2024, which is 24.27% up from last year.
  • Cullinan Therapeutics' Share-based Compensation amounted to $7.5 million in Q4 2023, which was down 2.86% from $7.7 million recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' Share-based Compensation registered a high of $12.1 million during Q4 2021, and its lowest value of $3.5 million during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $7.4 million (2022), whereas its average is $6.9 million.
  • Examining YoY changes over the last 5 years, Cullinan Therapeutics' Share-based Compensation showed a top increase of 106.67% in 2022 and a maximum decrease of 38.14% in 2022.
  • Cullinan Therapeutics' Share-based Compensation (Quarterly) stood at $12.1 million in 2021, then slumped by 38.14% to $7.5 million in 2022, then rose by 0.08% to $7.5 million in 2023.
  • Its Share-based Compensation was $7.5 million in Q4 2023, compared to $7.7 million in Q3 2023 and $7.9 million in Q2 2023.